To validate the therapeutic potential of the 2xAARE-YB system against solid tumors, NXG mice bearing CD19 + EST-109 tumors were i.v. and i.t. injected with mock, 2xAARE-YB-CAR-Jun- or EF1a-CAR-T cells, and tumor size was monitored every 3–4 days for three weeks. This evidence concerns the gene CD19 and neoplasm.